Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer
| Autor: | Shannon Puhalla, Rohit Bhargava, Emilia J Diego, David J. Dabbs, Alessandra Landmann, Adam Brufsky, Beth Z. Clark, Rachel C. Jankowitz, Priscilla F. McAuliffe, Daniel J. Farrugia, Gretchen M. Ahrendt |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
0301 basic medicine Oncology medicine.medical_specialty Neoplasm Residual Breast surgery medicine.medical_treatment Estrogen receptor Antineoplastic Agents Breast Neoplasms 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine Carcinoma Humans Mastectomy Survival analysis Neoadjuvant therapy Aged Retrospective Studies Aged 80 and over Chemotherapy business.industry Carcinoma Ductal Breast General Medicine Middle Aged Prognosis medicine.disease Survival Analysis Neoadjuvant Therapy Tumor Burden 030104 developmental biology Chemotherapy Adjuvant Lymphatic Metastasis 030220 oncology & carcinogenesis Female Neoplasm Grading business Algorithms Follow-Up Studies |
| Zdroj: | American Journal of Clinical Pathology. 149:332-343 |
| ISSN: | 1943-7722 0002-9173 |
| DOI: | 10.1093/ajcp/aqx168 |
| Popis: | Objectives We hypothesized that prognostic accuracy of the residual disease in breast and lymph nodes (RDBN) method, which is calculated using residual tumor size, nodal involvement, and tumor grade, may be improved by incorporating residual tumor cellularity. Methods Cases included 614 patients who underwent neoadjuvant therapy for breast cancer. Tumor size was adjusted for residual cellularity of invasive carcinoma and used to calculate modified RDBN (mRDBN) and compared with unmodified gross tumor size (gRDBN). Results RDBN could be calculated in 428 cases. Relative risks of recurrence and death were significantly higher for RDBN-3 and RDBN-4 compared with RDBN-1. Kaplan-Meier analysis showed significant differences in disease-free survival and overall survival for estrogen receptor (ER)-negative/human epidermal growth factor receptor 2 (HER2)-negative and ER-positive/HER2-negative subgroups (P < .0001). Conclusions Both mRDBN and gRDBN provide prognostic information, particularly in HER2-negative carcinoma; however, mRDBN showed better stratification of RDBN-3 and RDBN-4 patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|